News

TSC is a rare genetic disorder affecting about one million people globally, and Afinitor is the only approved non-surgical option indicated to treat non-cancerous brain and kidney tumours

Under the terms of the agreement, Evotec will manage Pierre Fabre’s compound collection (individual compounds and collection plates) out of its state-of-the-art compound management facility in Toulouse, France.

DYANAVEL XR is now available in U.S. pharmacies by prescription only. DYANAVEL XR is a federally controlled substance (CII) because it can be abused or lead to dependence.

The new 4500m2 facility will be opened by UK Life Sciences Minister George Freeman MP and GSK Chief Executive Officer Sir Andrew Witty. It is the latest expansion

Late in 2015, the company closed on a $50m Series A round, and completed its $100m Series B round this week. The most recent round was led by

The alliance will evaluate the potential for combining Astex’s guadecitabine (SGI-110) small molecule DNA hypomethylating agent with Genentech’s atezolizumab investigational anti-PD-L1 monoclonal antibody. The safety and pharmacology of

Ibrance is an oral inhibitor of CDKs 4 and 6, which are important regulators of the cell cycle that trigger cellular progression. The study met its primary endpoint

LAT Pharma brings a promising new therapeutic opportunity to NanoAntibiotics. Earlier this year LAT Pharma met with the FDA to discuss a submission for a novel therapy to

The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022. In December 2015, the Company